uniQure (NASDAQ:QURE) Cut to “Hold” at Royal Bank Of Canada

Royal Bank Of Canada lowered shares of uniQure (NASDAQ:QURE) from a moderate buy rating to a hold rating in a report published on Monday morning, Marketbeat Ratings reports. Royal Bank Of Canada currently has $11.00 target price on the biotechnology company’s stock.

A number of other research firms also recently weighed in on QURE. Wells Fargo & Company decreased their price objective on uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. Mizuho reduced their price target on uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, December 8th. Chardan Capital reissued a “buy” rating and issued a $53.00 price target on shares of uniQure in a research note on Thursday, December 4th. Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of uniQure in a report on Tuesday, February 10th. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $34.33.

uniQure Stock Up 0.1%

Shares of NASDAQ QURE opened at $9.04 on Monday. The company has a 50 day simple moving average of $22.54 and a 200 day simple moving average of $29.57. The firm has a market cap of $565.27 million, a PE ratio of -2.62 and a beta of 0.73. uniQure has a 1 year low of $7.76 and a 1 year high of $71.50. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 7.12.

uniQure (NASDAQ:QURE) last posted its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The firm had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. On average, research analysts forecast that uniQure will post -3.75 EPS for the current year.

Insider Transactions at uniQure

In other uniQure news, CFO Christian Klemt sold 6,217 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total transaction of $148,337.62. Following the transaction, the chief financial officer owned 211,513 shares in the company, valued at approximately $5,046,700.18. This represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director owned 20,439 shares in the company, valued at $557,575.92. This represents a 23.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 50,598 shares of company stock worth $1,248,588 in the last three months. Insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

Institutional investors have recently bought and sold shares of the stock. Private Trust Co. NA purchased a new position in uniQure during the 3rd quarter worth $28,000. Torren Management LLC bought a new position in shares of uniQure during the fourth quarter valued at about $28,000. Jones Financial Companies Lllp boosted its holdings in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the last quarter. IFP Advisors Inc purchased a new position in uniQure during the fourth quarter worth about $48,000. Finally, Smartleaf Asset Management LLC bought a new stake in uniQure in the 4th quarter worth about $48,000. Institutional investors own 78.83% of the company’s stock.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat expectations (EPS and revenue) and trading activity spiked after the release, which can support short‑term buying interest based on improved fundamentals and investor attention. uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume Following Strong Earnings
• Positive Sentiment: Technicals: analysts at Zacks note heavy recent selling has pushed QURE into oversold territory and consensus estimate revisions are moving higher — a technical + analyst alignment that could prompt a trend reversal or short‑covering bounce. uniQure (QURE) Loses 67.5% in 4 Weeks, Here’s Why a Trend Reversal May be Around the Corner
• Neutral Sentiment: Corporate/governance risk: uniQure disclosed it may fall under the Dutch “large company” regime next year, which would change shareholder control dynamics and could affect governance-related investor sentiment (longer‑term structural risk, not an immediate catalyst). uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments
• Negative Sentiment: Regulatory setback: the FDA has told uniQure to conduct another study of its Huntington’s gene therapy and senior FDA officials expressed doubt the current data demonstrate benefit. This materially weakens near‑term approval prospects and is the biggest immediate negative for the stock. FDA tells uniQure to conduct another study of Huntington’s gene therapy
• Negative Sentiment: Analyst downgrades and big price‑target cuts (Goldman, Wells Fargo, RBC, Mizuho and others) have followed the FDA news and earnings; several firms cut targets dramatically, lowering institutional support and amplifying selling pressure. uniQure (NASDAQ:QURE) Receives Equal Weight Rating from Wells Fargo & Company / price target changes
• Negative Sentiment: Legal/market risk: multiple law firms have filed or issued shareholder alerts about securities class actions tied to disclosures in late‑2025; active litigation and associated headlines increase legal risk and can deter investors. SHAREHOLDER ALERT: Berger Montague Reminds UniQure N.V. (QURE) Investors of Class Action Lawsuit Deadline

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.